Cell-mediated immunity to herpes simplex virus type 2 was investigated in infected inbred strain 13/N guinea pigs with (45%), and without, a history of recurrent herpetic disease (A. D. Donnenberg, E. Chaikof, and L. Aurelian, Infect. Immun. 30:99-109, 1980 ). Induction of suppressor cells capable of reducing the proliferative response of herpes simplex virus type 2-stimulated immune lymphoid cells was demonstrated in spleen cells from animals with a history of recurrent disease at recrudescence and convalescence but not in spleen cells from quiescent animals or from animals without a history of recurrent herpetic disease (seropositive controls). Suppressor cells were also detected in the peripheral blood but only from three of seven studied animals, and only at recrudescence. In addition to inhibitory cell-cell interactions, the herpes simplex virus type 2-activated regulatory cells of animals with recrudescent herpetic lesions elaborated soluble suppressor factors affecting lymphocyte proliferation. Suppression mediated by suppressor factors was observed only when suppressor factors were added at an early stage of in vitro culture and was reversed by medium exchange throughout the 6 days of culture. Sephadex chromatography revealed the presence of factors capable of differentially modulating the proliferative response of herpes simplex virus-stimulated immune cells and concanavalin A-stimulated normal lymphoid cells.
The hallmark of herpetic disease in humans is the ability of the virus to cause recurrent disease in a proportion of seropositive individuals. Recovery from infection with herpes simplex virus (HSV) is associated with the development of: (i) delayed-type hypersensitivity, a persistent response reflective of the establishment of immune memory (20, 23) , (ii) lymphoproliferation (LT) (15, 25) , an in vitro response that correlates with HSV-specific delayed-type hypersensitivity (22) , and is widely accepted as indicative of previous exposure to the antigen, and (iii) antigen-driven cell-mediated effector responses that can be measured in vitro, such as the production of lymphokines (3, 5, 26a) . However, approximately one half of the infected individuals exhibit recurrent disease that occurs as a consequence of the reactivation of latent virus (10, 26a, 27) . The observation that in the immunocompetent host, HSV lesions are self-limiting and of relatively short duration, whereas individuals with impaired cell-mediated immunity (CMI) suffer severe herpetic infections of endogenous origin (1, 18) , has led to the hypothesis that recurrent HSV disease is associated with regulatory defect(s) in virus-specific CMI (2, 6, 27) .
The following observations are pertinent with respect to the studies described in this report. The experimental design was made feasible by the development of a guinea pig model of recurrent herpetic disease (6, 26 (6) . Approximately 45% of the infected animals developed a history of recurrent disease within 1 to 4 months after infection and evidenced somewhat higher viral antibody titers than those without such history (seropositive controls) (6) .
Antigens. HSV-2 (G) was passaged twice in guinea pig embryo cells at 0.2 PFU/cell. Virus pelleted by centrifugation at 100,000 x g for 1 h, was resuspended in phosphate-buffered saline (PBS) to a final concentration of 3.2 x 107 PFU/ml (250 p.g of protein per ml) and inactivated by exposure to UV irradiation at 17 cm from a Sylvania G15T8 source for 30 min as described previously (5, 6) . This preparation was designated UV-HSV-2 (G).
In vitro culture of lymphoid cells. SC and PBL were obtained as described previously (5, 6 RESULTS HSV-2-induced LT response in animals with recurrent disease. SC and PBL obtained from guinea pigs with a history of recurrent disease at recrudescence (O to 7 days after onset of clinical symptoms), convalescence (8 to 14 days), and quiescence (>15 days) and from seropositive animals without a history of recurrent disease (seropositive controls) were grown in vitro in the presence of UV-HSV-2 (G) and assayed for
[3H]TdR incorporation at 3 and 6 days in cul-ture. Consistent with previous findings (6), LT responses were significantly higher in SC from seropositive controls than that from animals with a history of recurrent disease. In the latter group, the lowest responses were those of the SC obtained during recrudescence (Fig. 1) 387,073 ± 8,250 a PBL were obtained from animals, without a history of recurrent disease at 14 to 24 weeks after primary infection, that were seropositive for neutralizing antibody assayed as described in the text (seropositive controls) and from animals with virus-positive recrudescent lesions (0 to 7 days after the onset of symptoms), studied within 6 to 14 weeks after primary infection (recrudescent).
b PBL were cultured in vitro in the presence of UV-HSV-2 (G) antigen (6.0 ,ug of protein per ml) and assayed for [3H]TdR incorporation on day 6 in culture.
c LT responses in cultures of PBL obtained at quiescence and convalescence were virtually identical to those observed in seropositive controls.
duced levels (58 to 85%) of [3H]TdR incorporation (Fig. 2) . A similar reduction was not observed in cultures in which the regulators were SC obtained during quiescence, even if these were differentiated or amplified by 3 days of in vitro growth in the presence of UV-HSV-2 (G) before mixing (Table 2 ). In PBL cultures (Fig. 2C) (Fig. 3) (Fig. 2) , contain SF(s) capable of suppressing HSV-induced lymphoproliferation. The levels of SF activity in the supernatants increased as a function of time in culture, reaching maximal values on days 4 to 5 (Fig. 4) .
Effects of SF on LT response. Cultures of UV-HSV-2 (G)-stimulated immune responder cells grown in the presence or absence of SF (20% final concentration) added at initiation (day 0) were assayed for [3HJTdR incorporation on days 1, 3, 5, and 6. LT responses increased exponentially throughout the first 5 days (Fig. 5A) 6. b SC obtained during quiescence were grown for 3 days in the presence of UV-HSV-2 (G) (6. The dose-response relationship for SF inhibition of UV-HSW-2 (G)-stimulated proliferation is shown in Fig. 5B . Dilutions of SF >1:20 were routinely not suppressive. The effects of the delayed addition of SF on UV-HSV-2 (G)-induced proliferation is shown in Fig. 5C . The addition of SF after the initial 24 h of antigen stimulation greatly reduced its suppressive potential. The addition of SF at 3 days failed to produce suppression, suggesting that the SFmediated inhibition of cell growth results from the interruption of a relatively early event in the lymphocyte activation sequence.
The SF-induced suppression of HSV-stimulated proliferation, is reversible (Table 4) 6A) . On the other hand, two fractions with approximate molecular weights of 50,000 to 60,000, and 110,000 to 160,000, respectively (Fig. 6B) , did not suppress the ConA-induced proliferation but exhibited strong suppressive activity for UV-HSV-2 (G)-stimulated immune responder SC. Kinetics of SF production. SC obtained at recrudescence were grown in presence of UV-HSV-2 (G) (6.0 ,ug of protein per ml), and the supernatants collected on days 1 (D1-S), 3 (D3-S), 4 (D4-S), and 5 (D5-S) in culture were assayed for SF activity at a final concentration of 50%. The assay was as described in the legend to Fig. 3 a Immune responder SC were grown with UV-HSV-2 (G) in the presence of SF (30% final concentration) added on day 0. On days 2, 3, 4, and 6 the cells were centrifuged (300 x g, 10 min) and suspended in fresh RPMI-10% GPS. They were reincubated at 37°C and assayed for [3H]TdR incorporation on days 1, 3, 5, and 6. Similar results were obtained with fresh RPMI-10% GPS containing UV-HSV-2 (G) (6. (8, 20) . Despite some evidence to the contrary (21) , it appears that suppression by these lectin-activated cells involves, at least in part, the elaboration of several short-range factors that inhibit target cell function. Indeed, ConA-activated human lymphocyte supernatants were shown to contain suppressor factors that inhibit the mixed leukocyte reaction (16, 30) , mitogen-and antigen-stimulated T-cell proliferation, and B-cell immunoglobulin production (13, 29) .
In the present study, experiments were designed to determine whether the suppression mediated by lymphoid cells obtained at recrudescence ( Fig. 1 and 2 ) requires cell to cell contact or whether it could be mediated by soluble SF(s) released by these cells. Our findings indicate that SC obtained during recrudescence and grown in vitro in the presence of UV-HSV-2 (G) produce soluble SFs that are released into the culture medium. These factors dampen the UV-HSV-2 (G)-stimulated proliferation of the cells that elaborate them (feedback inhibition) (Table 3) , the HSV-stimulated responses of immune responder cells (Fig. 3 and 5 and Table  4 ) and the ConA-stimulated LT responses of normal lymphocytes (Fig. 6A) . Suppression was not mediated by the viral proteins themselves, since it was reversed by SF-free medium supplemented with 6.0 ,g of UV-HSV-2 (G) per ml (Tables 3 and 4 ). However, Sephadex molecular sieve chromatographic profiles (Fig. 6) , suggest that factors involved in the suppression of HSVinduced DNA synthesis by the immune cells differ from those involved in the suppression of ConA-induced proliferation of normal lymphoid cells.
At present, we do not know whether the various fractions containing SF activity represent structurally similar or different molecular entities, nor whether the high-molecular-weight factor(s) are also capable of inhibiting proliferation induced by antigens other than HSV. Furthermore, the mechanism of SF action is still unclear. Most of our studies were done with unfractionated supernatants, thereby precluding final conclusions pertaining to the suppressive effects of the apparently different SF moieties and their respective role in the pathogenesis of herpetic disease. However, suppression of DNA synthesis in HSV-stimulated immune lymphoid cells was only observed when SF was added at early stages (day 0 to 1) of the culture period (Fig. SC) , suggesting that SF exerts its influence on an initiation event. In the presence of SF, the onset of the proliferative response was delayed by 1 day (Fig. 5A) , and the maximal levels of
[3H]TdR incorporation were significantly decreased (Fig. 5B) . However, as evidenced by identical doubling times in SF-treated and untreated cultures (Fig. 5A) , SF did not modify the antigen sensitivity (5) of the lymphoid cells. SFmediated suppression was reversible throughout the 6 days of in vitro culture (Tables 3 and 4 ), indicating that suppression is not merely a consequence of toxicity. Taken in toto, the findings are consistent with the interpretation that SF interacts with defined cell surface receptors that represent inhibitory domains within the cell membrane (24) . The cell population involved in SF synthesis, the structural identity of the various SF fractions detected in these series, and their respective roles in the pathogenesis of the disease remain to be established.
It may be profitable to consider the findings within the context of our previously stated hypothesis (2, 6, 27) of virus-specific CMI at the center of the recurrent disease problem. This hypothesis predicts that the development of clinically visible recurrent lesions is controlled at two sequential levels. The first control, the mechanism of which remains unclear (14) , is postulated to occur at the level of persistently infected cells and to result in increased virus replication (reactivation). As evidenced by the finding that virus shedding can occur in the absence of overt lesions (7, 14, 17) , reactivation does not necessarily result in clinical symptoms. According to our hypothesis, virus reactivation provides the necessary stimulus for the generation of an anamnestic effector response capable of checking virus spread. A lag in the generation of this response, such as might result from the development of specific suppressor functions, would favor virus replication, thereby resulting in clinically apparent lesions.
Although cause and effect cannot be argued from the data presented in this report, our findings support this interpretation. Suppressor cells are observed during recrudescence in both the spleen and the peripheral blood, and they produce SFs that dampen the proliferative responses of the cultures that elaborate them. The proportion of suppressor cells decreases with time after lesion onset. In the spleen (but not PBL), suppressor cells are still detectable during convalescence. However, their proportion is lower, as evidenced by the finding that twice as many convalescent as compared to recrudescent SC, are required to reduce the 2-day lymphoproliferative response by one half (Fig. 2A) . Suppressor cells are no longer detectable during quiescence, even when SC (or PBL) are differentiated or amplified by 3 days of in vitro growth in the presence of viral antigen. These findings suggest that at recrudescence, suppressor cells are induced by reactivated virus. Similar findings were obtained in exogenously reinfected HSV-2 seropositive animals (J. F. Sheridan et al., manuscript in preparation).
The following are implicit in these interpretations. First, during quiescence, suppressor cells or their precursors must persist at a site other than the spleen or the peripheral blood. This site may be the lymph nodes. Indeed, we find that suppressor cells differ in their distribution at different stages of the herpetic disease (viz. SC versus PBL), and different tissue distribution of various cell subpopulations has been independently demonstrated (11, 12, 15, 19) . Secondly, the impaired LT responses of SC obtained during quiescence (as compared to seropositive controls [6; Fig. 1] ) may reflect the presence of fewer cells that are committed to proliferate in the presence of HSV antigen, or cells with lower antigen avidity. Mathematical modeling of lymphoproliferative responses based on exponential growth as a function of time and logistic growth as a function of log antigen dose supports this interpretation (Donnenberg, Ph.D. thesis). However, final conclusions must await the results of limiting dilution studies, presently in progress in our laboratory, that are designed to define the frequency of HSV-responsive cells at different stages of the recurrent herpetic disease cycle.
